Cognition enhancing effect of panax ginseng in Korean volunteers with mild cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial.
Clinical Trial
Cognition
Panax Ginseng
Seoul Neuropsychological Screening Battery (SNSB)
Journal
Translational and clinical pharmacology
ISSN: 2383-5427
Titre abrégé: Transl Clin Pharmacol
Pays: Korea (South)
ID NLM: 101639331
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
18
07
2019
revised:
21
09
2019
accepted:
23
09
2019
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
15
2
2020
Statut:
ppublish
Résumé
This study aimed to investigate the cognition-enhancing effect of Panax ginseng. A randomized, double-blind, placebo-controlled clinical trial was conducted to address the cognition-enhancing effects of Panax ginseng. A total of 90 Korean volunteers with mild cognitive impairment participated in this study. All subjects were allocated randomly into 'Ginseng' group or 'Placebo' group. All subjects were administered 3g of Panax ginseng powder or starch (placebo) for 6 months. The Korean version of the Mini-Mental Status Examination (K-MMSE), Korean version of Instrumental Activities of Daily Living (K-IADL), and Seoul Neuropsychological Screening Battery (SNSB) were used to assess the changes in cognitive function at the end of the 6 month study period. The subjects of the 'Ginseng' group improved significantly on the Rey Complex Figure Test (RCFT) immediate recall (P = 0.0405 and P = 0.0342 in per-protocol (PP) and intention-to-treat (ITT) analysis, respectively) and on the RCFT 20-min delayed recall (P = 0.0396 and P = 0.0355 in PP and ITT analysis, respectively) compared with 'placebo' group throughout the 6 months of Panax ginseng administration. There were no serious adverse events. These results suggest that Panax ginseng has a cognition-enhancing effect.
Identifiants
pubmed: 32055589
doi: 10.12793/tcp.2019.27.3.92
pmc: PMC6989239
doi:
Types de publication
Journal Article
Langues
eng
Pagination
92-97Informations de copyright
Copyright © 2019 Translational and Clinical Pharmacology.
Déclaration de conflit d'intérêts
Conflict of interest: - Authors: Nothing to declare - Reviewers: Nothing to declare - Editors: Nothing to declare
Références
Eur J Neurol. 2008 Aug;15(8):865-8
pubmed: 18684311
Brain Res. 1994 Jun 27;649(1-2):7-11
pubmed: 7953656
Biol Pharm Bull. 2009 Oct;32(10):1710-5
pubmed: 19801832
Brain Res. 2009 Feb 23;1256:111-22
pubmed: 19133247
Neuroreport. 1998 May 11;9(7):1619-24
pubmed: 9631476
Biochem Pharmacol. 1999 Dec 1;58(11):1685-93
pubmed: 10571242
J Alzheimers Dis. 2009;18(2):339-44
pubmed: 19584437
Phytother Res. 2010 Dec;24(12):1748-54
pubmed: 20564503
Physiol Behav. 2002 Apr 15;75(5):739-51
pubmed: 12020739
Aging (Milano). 1996 Dec;8(6):417-20
pubmed: 9061129
Nutr Neurosci. 2001;4(4):295-310
pubmed: 11842896
Pharmacol Biochem Behav. 2003 Jun;75(3):687-700
pubmed: 12895687
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Behav Brain Res. 2009 Aug 12;201(2):311-7
pubmed: 19428650
Chin Med J (Engl). 1990 Nov;103(11):932-8
pubmed: 2177392
Nutr Neurosci. 2001;4(5):399-412
pubmed: 11842916
Nat Prod Res. 2011 Apr;25(7):704-15
pubmed: 20628966
Biol Pharm Bull. 1995 Oct;18(10):1439-42
pubmed: 8593452
Brain Res. 2011 Mar 25;1382:147-54
pubmed: 21276426
Brain Res Mol Brain Res. 1997 Jul;47(1-2):177-82
pubmed: 9221915
J Pharmacol Exp Ther. 2002 Jun;301(3):1052-9
pubmed: 12023537
Biol Pharm Bull. 1995 Apr;18(4):518-22
pubmed: 7655419
Planta Med. 2001 Aug;67(6):533-7
pubmed: 11509974
Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):222-6
pubmed: 18580589
J Ethnopharmacol. 2008 Feb 12;115(3):441-8
pubmed: 18083315